$6.30
9.95% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US88032L2097
Symbol
TENX

Tenax Therapeutics, Inc. Stock price

$6.30
+0.97 18.20% 1M
+3.32 111.41% 6M
-15.67 71.32% YTD
-17.14 73.12% 1Y
-1,641.70 99.62% 3Y
-2,021.86 99.69% 5Y
-121,593.70 99.99% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.57 9.95%
ISIN
US88032L2097
Symbol
TENX
Sector

Key metrics

Market capitalization $21.48m
Enterprise Value $-76.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 6.17
P/B ratio (TTM) P/B ratio 0.22
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-15.54m
Free Cash Flow (TTM) Free Cash Flow $-12.46m
Cash position $98.31m
EPS (TTM) EPS $-15.94
Short interest 4.10%
Show more

Is Tenax Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Tenax Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Tenax Therapeutics, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Tenax Therapeutics, Inc. forecast:

Buy
100%

Financial data from Tenax Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
67% 67%
-
-0.01 -0.01
67% 67%
-
- Selling and Administrative Expenses 5.71 5.71
21% 21%
-
- Research and Development Expense 9.81 9.81
269% 269%
-
-16 -16
109% 109%
-
- Depreciation and Amortization 0.01 0.01
67% 67%
-
EBIT (Operating Income) EBIT -16 -16
109% 109%
-
Net Profit -15 -15
107% 107%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tenax Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tenax Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
about one month ago
Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Seamus Fernandez Good afternoon, everybody. And welcome again to Guggenheim Securities Inaugural Healthcare Innovation Con...
Neutral
GlobeNewsWire
about 2 months ago
Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors
Neutral
GlobeNewsWire
about 2 months ago
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Mas...
More Tenax Therapeutics, Inc. News

Company Profile

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Head office United States
CEO Christopher Giordano
Employees 5
Founded 1967
Website www.tenaxthera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today